Cargando…
Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice
Biologicals are established treatment options that require pharmacovigilance adapted to their specific nature, including the need for products to be identifiable up to the specific manufacturer in reports of adverse drug reactions (ADRs). This study explored the identifiability of 10 classes of simi...
Autores principales: | Vermeer, Niels S., Giezen, Thijs J., Zastavnik, Sofia, Wolff‐Holz, Elena, Hidalgo‐Simon, Ana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590109/ https://www.ncbi.nlm.nih.gov/pubmed/30460997 http://dx.doi.org/10.1002/cpt.1310 |
Ejemplares similares
-
Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions
por: Correia Pinheiro, Luis, et al.
Publicado: (2021) -
Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars
por: Alsamil, Ali M., et al.
Publicado: (2021) -
Adverse Drug Reaction Reporting by Patients in 12 European Countries
por: Valinciute-Jankauskiene, Agne, et al.
Publicado: (2021) -
Plethora of adverse drug reactions in geriatric population receiving statin therapy for dyslipidaemia
por: Padhye, Mugdha R., et al.
Publicado: (2022) -
Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN)
por: Kuijper, E.C., et al.
Publicado: (2020)